ProPhase Labs, Inc. filings document material events, capital-structure changes, listing status, and operating updates for an OTC-traded life sciences, diagnostics, genomics and consumer health company. Form 8-K disclosures cover the BE-Smart™ esophageal cancer risk stratification test, Crown Medical Collections activity involving legacy COVID-19 testing receivables, shareholder communications, and updates on underlying assets.
The company’s SEC record also includes disclosures on common stock listed for OTC trading under PRPH, a Nasdaq Form 25 delisting notice, a reverse stock split, convertible debt conversions, an equity line stock purchase agreement, related warrant issuance, and unregistered equity sales. Periodic-reporting records include an NT 10-K notice tied to the year-end financial reporting process.
ProPhase Labs, Inc. is soliciting proxies for a Special Meeting of stockholders to vote on six proposals at a meeting on August 29, 2025, including amendments to equity plans, a major increase in authorized common stock, a shareholder repurchase program, approval of a recent private placement, and a bylaw amendment to add the company address. The Board recommends that stockholders vote FOR Proposals 1 through 6.
Key figures disclosed include 41,541,205 shares outstanding as of the record date, a proposal to increase the company’s authorized common shares from 50,000,000 to 1,000,000,000 to enable a stated crypto treasury strategy, an increase of 3,000,000 shares for the employee equity plan and 500,000 shares for the directors’ plan, a non-binding share repurchase program authorizing up to $15 million in buybacks, and shareholder approval sought for issuance of up to 226,310,704 shares (and/or convertible/exercisable securities) in connection with a private placement entered into on July 22, 2025 that may result in issuance exceeding 20% of outstanding shares. The proxy discloses governance features for the proposed plans, including no discounted options, no repricing without shareholder approval, independent committee administration, no evergreen provision, and clawback provisions for awards.
ProPhase Labs filed an amended 8-K to disclose material loan agreements executed on June 22, 2025. The company entered into two identical loan arrangements:
- Two $500,000 non-convertible loans with: - CEO/Chairman Ted Karkus (related party transaction) - An unaffiliated investor
- Key loan terms: - 20% original issue discount - 10% annual interest rate - 12-month maturity - Secured but subordinate to other potential lenders up to $6M - Prepayment allowed without penalty
- Each loan includes 500,000 unvested warrants to purchase common stock at $0.60 exercise price, subject to shareholder approval of authorized share increase
The Audit Committee approved the related-party transaction with Karkus, who receives a $10,000 non-accountable expense reimbursement. The warrant issuance was made under Securities Act Section 4(a)(2) exemption and Rule 506 of Regulation D.
ProPhase Labs (Nasdaq: PRPH) filed an 8-K disclosing two identical $500,000 secured loans executed on June 22 2025 with CEO Ted Karkus (a related-party) and an unaffiliated investor.
- 20% original-issue discount; company receives $400k per loan
- 10% annual interest; 12-month maturity; prepayable anytime
- Loans are subordinate to up to $6 million of future senior debt
- Company pays the CEO a $10,000 expense reimbursement
- Issued 500,000 unvested warrants at a $0.60 strike, vesting only after shareholder approval of additional authorized shares
The Audit Committee approved the related-party terms. The warrant issuance relies on Rule 506 of Regulation D. The filing creates a new financial obligation, unregistered equity issuance, and potential dilution, affecting near-term liquidity and governance optics.